Fig. 2From: Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homingRepresentation of the orthopedic assessment and CBPI over time and gross pathology results. Treatment groups (± SD) over time are shown for lameness (A), articular pain (B), joint effusion (C), pain severity (D), pain interference (E), and gross pathology (F). Data presented as mean ± SDBack to article page